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ABSTRACT
Blood and urine biochemistry screening tests are important for initial detection of diabetes, deter-
mination of severity of its complications, and monitoring of therapy. We evaluated the effects of
aqueous chicory seed extract (CSE), on renal biochemical parameters, histology, and Naþ/glucose
cotansporters, SGLT1 and SGLT2 expression levels using metformin, and aspirin as controls. Late
stage type 2 diabetes (LT2D; FBS,>300mg/dl) and early stage type 2 diabetes (ET2D; FBS,
140–220mg/dl) were induced in rats by streptozotocin (STZ group) and a combination of STZ
and niacinamide (NIA/STZ group), respectively. A non-diabetic group was included as control.
Treatment included daily intraperitoneal injections of either CSE (125mg/kg b.w.) or metformin
(100mg/kg b.w.) and oral aspirin (120mg/kg b.w.) for 21 days. At the end, blood and 24h urine
samples were collected; and kidneys were saved at 80 ˚C. CSE reduced urinary a1-microgobulin
excretion in ET2D (p¼ .043), and serum uric acid (p¼ .045), and glomerular diameter (p< .01) in
LT2D. Metformin appeared to be more effective in LT2D with respect to serum uric acid, urea,
and BUN (< .05). Both CSE and metformin improved histology. Aspirin improved several blood
and urine variables, but appeared to aggravate morphological damages to the kidney tissue. The
absolute values of albumin, a1-microglobulin or total protein in urine rather than their creatinine
ratios seemed more useful in the detection of early kidney damage; CSE was able to repair the
kidney damage and a1-microglobulin was sensitive enough to allow monitoring of the improve-
ments caused by the treatment.
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Introduction
A healthy kidney is essential for glucose homeostasis.
Kidney filters glucose and subsequently reabsorbs the
filtered glucose or excretes it into urine; it uptakes glu-
cose for its energy needs; and also releases into circula-
tion the glucose that it has newly synthesized via
gluconeogenesis.1 Obesity, metabolic syndrome, and
diabetes generate unfavorable changes in the kidney
tissue and alter its functions.
Chronic kidney disease (CKD) can be initiated by
hyperglycemia and lead to diabetic nephropathy (DN),
which is the major cause of end-stage renal disease
(ESRD).2 Evidence suggests that DN develops much ear-
lier in the course of the disease; there seems to be 4–7
years of asymptomatic phase between the onset of
hyperglycemia and the actual clinical diagnosis of type
2 diabetes (T2D). During this lag period, chronic compli-
cations of diabetes, such as nephropathy, retinopathy,
and cardiovascular disease that are caused mainly by
micro- and macro-vascular changes in the endothelium
of blood vessels, and metabolic acidosis, continue to
develop in disguise.3,4
Although microalbuminuria is an important stage of
kidney disease in diabetes,5 it has been reported that
kidney damage can occur without evident proteinuria
or microalbuminuria. High-fat diet, for example, can
cause significant kidney damage without any evidence
of proteinuria or hyperglycemia. In addition, hypergly-
cemia and hypertension are needed for the presence of
protein in urine.6,7 But, as diabetic patients often suffer
from both hyperglycemia, hyperlipidemia, as well as
hypertension, they are susceptible to kidney complications;
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therefore, traditional biomarkers including macro and
microalbuminuria, and creatinine, as a marker of estimated
glomerular filtration rate (eGFR), can still be used in the
detection and monitoring of kidney damages.8–13
We have previously shown the hypoglycemic and
antihyperlipidemic effects of lyophilized Cichorium inty-
bus L. aqueous seed extract (CSE).14,15 The aim of the
present study was to test the usefulness of CSE in pre-
venting diabetes-induced kidney damage. A number of
DN biomarkers, such as urea, BUN, uric acid, creatinine,
albumin, a1-microglobulin, total protein, sodium, potas-
sium, and GFR were measured in serum and urine, and
in the renal tissue samples of rats with early type 2 dia-
betes (ET2D) and late type 2 diabetes (LT2D).16 We also
noted kidney histology and the expression of Naþ/glu-
cose cotransporters in kidney tissue homogenates.
Metformin and aspirin were used as controls.
Materials and methods
All the experiments were performed on the sera, urine
samples and kidney tissues obtained from rats used in
another study.16
Preparation of plant extract, metformin and
aspirin
The lyophilized powder of CSE that was stored at
20 C belonged to a previous study from our labora-
tory.14 Metformin and aspirin pills (Chemidaru industrial
company, Tehran, Iran) were purchased from a drug
store and crushed manually.
Animals
Animal care
Animal handling and treatment were performed in the
Biochemistry Department of the School of Medicine,
Tehran University of Medical Sciences (TUMS). Healthy
adult male 8-week old Wistar albino rats weighing
190–260 g were obtained from University of Tehran,
Institute of Biochemistry and Biophysics and housed in
standard and clean cages (2 per cage) in animal room
(temperature 22± 2 C) and 12-h light/dark cycle with
access to a standard rat chow and water ad libitum. The
study was ethically approved by the review board of
TUMS.
Induction of experimental diabetes
In brief, early and late stage type 2 diabetes (ET2D and
LT2D) were induced in overnight fasted rats by single
intraperitoneal injections of streptozotocin (STZ, 55mg/kg)
or combination of STZ (55mg/kg) and niacinamide (NIA,
200mg/kg, 15min later), dissolved in chilled citrate buffer
(0.3ml).14 Hyperglycemia was confirmed on days 4 and 10
after injection by measuring glucose levels in peripheral
blood obtained from the tail vein (GlucoSure STAR,
ApexBio, Taiwan). STZ-injected rats with fasting blood
sugar (FBS) above 300mg/dl in both occasions (day 4 and
day 10) were considered as LT2D rats, and NIA/STZ-
injected rats with stable FBS ranging between 140 and
220mg/dl were considered as ET2D.16 Normal rats
received an injection of the vehicle without either STZ or
NIA. STZ and NIA were obtained from Sigma-Aldrich Co.
(St. Louis, MO).
Experimental design, group designation and
treatment
After diabetes induction, rats were assigned into nine
groups (n¼ 6) as presented in Figure 1 and treatment
was started on day 10. Groups 1 (Control, non-diabetic),
3 (NIA/STZ or ET2D), and 6 (STZ or LT2D) received injec-
tions of the vehicle (0.3ml). Groups 2 (CSE-control), 4
(CSE-NIA/STZ), and 7 (CSE-STZ) were injected with CSE.
Groups 5 (Met-NIA/STZ) and 8 (Met-STZ) were injected
with metformin. The injections of CSE and metformin
were daily and intraperitoneal, and lasted for 21 days (3
weeks); Group 9 (Asp-STZ) received daily aspirin orally
by gavage. According to weekly body weights, certain
amounts (mg) of CSE, metformin, and aspirin were pre-
weighed in separate microtubes and kept in refriger-
ator; they were mixed with 0.3ml of manually prepared
and autoclaved citrate buffer (20mM, pH 4.5) immedi-
ately before administration.16
Sample collection
At the end of the treatment time (day 31), animals were
placed individually in metabolic cages for 24 h urine col-
lection with access to water overnight. After measuring
the volume, urine samples were acidified with 1ml of
0.1 M HCL and centrifuged at 1200 rpm for 15min; ali-
quots were stored at 80 C. The rats were anesthetized
Figure 1. Rat groups. Duration of treatment, 21 days.
Treatments included: CSE, 125mg; metformin, 100mg; and
aspirin, 120mg; per body weight per day.
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with diethyl ether and sacrificed. Blood samples were
collected for biochemical analysis by direct cardiac
puncture and sera were separated by centrifugation at
3000 rpm for 15min. The kidneys were submerged in
liquid nitrogen after separation from the body and
stored at 80 C.
Biochemical analysis
Measurement of urea, uric acid, creatinine and albumin
in serum and urine was performed by spectrophotomet-
ric methods using diagnostic kits (Ziest Chem
Diagnostics, Tehran, Iran). A kit from the same company
based on the Biuret method was used to determine total
protein in the serum, and the Bradford method was used
to measure total protein in tissue homogenates and urine
samples.17 ELISA (NovaTeinBio, Woburn, MA) was used to
measure a1-microglobulin in serum and urine. Sodium
and potassium levels in serum were measured by flame-
photometry. Glucose level in urine was measured by glu-
cose oxidase activity assay kit (Ziest-Chem, Iran). GFR was
calculated according to the following formula:
Clearance ðmg=minÞ ¼ Urine Creatinine ð
mg
dl ÞUrine Volume ðmlÞ
Serum Creatinine mgdl
 1440
Histological observation
A small piece of frozen kidney tissues of all groups were
fixed in an aqueous solution of 10% formaldehyde,
dehydrated in graduated ethanol (50–100%), cleared in
xylene, and embedded in paraffin. Renal sections (5 lm)
were examined with a photomicroscope (400) after
staining with hematoxylin and eosin (H&E) dye.
Membrane preparation for SGLT1 and SGLT2 blotting
Half of each kidney tissue was homogenized in chilled
buffer A (137mM NaCl, 8.1mM Na2HPO4, 2.7mM KCl,
1.5mM KH2PO4, 2.5mM EDTA, 1mM dithiothreitol,
0.2mM PMSF, mM cocktail) by hand homogenizer and
further by trituration with insulin syringe. Lysates were
first centrifuged at 6000g for 15min at 4 C. The super-
natants were centrifuged at 120,000g for 1 h at 4 C to
prepare cytosolic and total particulate fractions. The
total particulate fractions, which contained membrane
fraction, were washed twice and resuspended in buffer
A containing 1% (v/v) Triton X-100.18 After centrifuga-
tion, the protein in each fraction was quantified by the
Bradford procedure.
Western blot analysis
For each electrophoresis lane, equal amounts of protein
(30 lg) were mixed with loading buffer and boiled for
five minutes. Samples were separated on an 8% sodium
dodecyl sulfate-polyacrylamide gel and then transferred
to polyvinylidene fluoride (PVDF) membrane. PVDF
blots were blocked by incubation in PBST (20mM PBS,
pH 7.4, and 0.1% Tween 20) containing 5% nonfat skim
milk overnight at 4 C and then incubated with a rabbit
polyclonal antibodies against SGLT1 (1: 1000 dilution),
SGLT2 (1: 200 dilution), and b-actin (1: 3000 dilution) for
2 h at 37 C (Abcam Inc., Cambridge, MA). After three
washing steps (PBST, each step 5min), a horseradish
peroxidase (HRP)-conjugated polyclonal secondary anti-
rabbit antibody (1: 20,000 dilution) was added and incu-
bated for 1 h. After three washing steps, the bands were
visualized with enhanced chemiluminescence detection
kit (ECL) (Thermo Scientific, Waltham, MA). Image J soft-
ware (NIH) was used for densitometric analysis of the
bands.
Statistical analysis
Statistical analysis was performed by SPSS software (ver-
sion 20, Chicago, IL). Normal distribution of continuous
variables was checked by the Kolmogrov–Smirnov test
in each group. All variables in each group had normal
distribution, so the comparison of continuous variables
between different groups was carried out by one-way
analysis of variance (ANOVA) followed by the Scheffe
and Dunnett T3 post hoc tests. Data were presented as
the mean± standard deviation (SD). The level of signifi-
cance was considered .05. Pearson coefficients were
measured for association between continuous variables.
Results
Body weights and FBS
After diabetes induction, FBS levels increased signifi-
cantly to>300mg/dl in STZ groups (LT2D), and ranged
between 140 and 220mg/dl in NIA/STZ groups (ET2D);
the LT2D rats lost significant weight, but weight loss
was not significant in NIA/STZ-induced diabetes
(ET2D).16 The percent changes of FBS and body weight
at the end of treatment (day 31) versus start of treat-
ment (day 10) are shown in Figure 2; CSE significantly
lowered FBS (p< .001) and increased body weight
(p¼ .032) in ET2D rats.
Blood and urine parameters in the final day of
treatment (day 31)
Untreated diabetic groups
Induction of LT2D led to significant increase in several
serum variables, including uric acid (p¼ .04), creatinine
(p< .001), urea (p¼ .001), and BUN (p¼ .001); and a
RENAL FAILURE 3
decrease in albumin levels (p¼ .047) (Table 1). Again in
serum, changes common to both types of diabetes were a
decrease in Naþ (p¼ .007) due to diabetic hyperosmolar
state, an increase in Kþ (p< .001) due to lack of enough
insulin and the resulting disturbances of internal potas-
sium balance, and a decrease in serum a1-microglobulin
levels (p¼ .002 for LT2D; p¼ .011 for ET2D).19–21 Urine vol-
ume (p< .001 for LT2D; p¼ .01 for ET2D), a1-microgobulin
(p¼ .001 for LT2D; p¼ .006 for ET2D), and total protein
(p¼ .006 for ET2D; p¼ .018 for LT2D) increased after induc-
tion of both types of diabetes (Table 2). Urinary levels of
glucose (p¼ .001), uric acid (p¼ .002), creatinine (p¼ .005),
and urea (p< .001) increased in LT2D, and albumin levels
increased in ET2D (p¼ .042). There was a strong correl-
ation between 24h urine urea and creatinine perhaps due
to excessive loss of muscle mass (Figure 3(A); Pearson
correlation¼ .889, p< .001). Correlation between urine a1-
microglobulin and serum uric acid was stronger (Pearson
coefficient¼ .811, p¼ .001) than the correlation between
urine albumin and serum uric acid (Pearson coef-
ficient¼ .399, p¼ .112) (Figure 3(B,C)).
CSE-treated groups
CSE treatment decreased the level of urea (p¼ .005),
BUN (p¼ .005), and Kþ (p¼ .006), and increased Ta
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Naþ (p¼ .037) in serum; it also significantly decreased
urinary a1-microglobulin (p¼ .043) in CSE-STZ/NIA rela-
tive to the NIA/STZ group. In LT2D, uric acid levels in
serum (p¼ .045), urine volume (p¼ .012), and urinary
glucose (p¼ .021) decreased in the CSE-STZ group
(Tables 1 and 2).
Metformin-treated groups
In ET2D, treatment with metformin did not affect blood
or urine biochemistry. In LT2D, metformin lowered
blood concentrations of uric acid (p¼ .021), urea
(p¼ .012), and BUN (p¼ .012); it also decreased urine
glucose (p¼ .002) and urea (p¼ .001) (Tables 1 and 2).
Aspirin-treated group
Urea (p¼ .001) and BUN (p¼ .001) decreased and cre-
atinine (p< .001) increased in blood under aspirin.
Aspirin significantly reduced the urine volume
(p< .001), and urinary levels of glucose (p¼ .001), uric
acid (p¼ .042), urea (p¼ .002), and total protein
(p< .05) in Asp-STZ relative to the STZ group (Tables 1
and 2).
Histological observation
Kidney histology for normal rats (Control and CSE-
control) and for those with ET2D and LT2D are shown
in Figures 4–6. The average values of glomerular diame-
ters measured from three perspectives for 10 glomeruli
in each group are given in Table 2. When compared to
STZ-group, CSE caused a reduction in average glomeru-
lar diameter (p¼ .007). Aspirin, on the other hand,
seemed to increase glomerular diameter (p¼ .83).
Western blot analysis
The expression levels of SGLT1 and SGLT2 proteins
increased significantly in the kidney tissue after diabetes
induction (p< .01). Treatment with CSE increased SGLT1
(p< .01), but did not change the SGLT2 levels (Figure 7).
Discussion
In diabetes, flesh and limbs flow into urine to produce
alterations in urine and blood variables.22 To evaluate
some of these variables, we created sets of diabetic ani-
mals with ET2D and LT2D (LT2D may be taken as
equivalent to uncontrolled insulin-deficient diabetes).
Increase in FBS and urine output, low insulin in ET2D
and lack of insulin in LT2D rats, in addition to behav-
ioral changes such as aggressiveness and fatigue, were
a proof for diabetes induction. The significantly alteredTa
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biochemical parameters are shown in bold and italic
fonts in Tables 1 and 2.
In ET2D rats, CSE had ameliorating effects on FBS,
urea, BUN, a-1-microglobulin, sodium, and potassium,
in serum. In urine of ET2D rats, the most pronounced
effect of CSE was on a-1-microglobulin levels. CSE and
metformin were similar in causing a non-significant
reduction in urine albumin levels, but only CSE was able
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Figure 3. Correlation coefficients between 24 h urine urea and creatinine (A), urine albumin and serum uric acid (B), and urine
a1-microglobulin and serum uric acid (C).
Figure 4. H & E stained optical micrographs of kidney tissue morphology of normal non-diabetic rats before (Control) and after
(CSE-control) treatment with chicory (400). G: glomerulus; US, urinary space; DCT: distal convoluted tubules; UP: urinary pole.
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to significantly lower urine a1-microglobulin.
Although creatinine excretion increases in diabetes,
the urinary protein levels are frequently normalized to
urinary creatinine concentration.13 No significant
change was observed in urinary albumin/creatinine or
a1-microglobulin/creatinine ratios across the groups. It
seemed that early engagement of the kidneys could
be anticipated from abnormal absolute values of albu-
min, a1-microglobulin or total protein in urine rather
than their creatinine ratios; only CSE seemed able to
reverse the kidney problem and only a1-microglobulin
was sensitive enough to successfully show improve-
ments that followed treatment. a1-Microglobulin is a
low molecular weight glycoprotein. The free form
completely filters through the glomeruli and then is
reabsorbed completely by normal proximal tubules.
Its urine levels provide information about the renal fil-
tration and reabsorption capacity of low molecular
weight proteins.13
Elevated uric acid in serum (>8mg/dl) and its low
urinary excretion are associated with higher risk of T2D
and increased chance of renal insufficiency by 3 fold in
men and 10 fold in women.23–26 In the present study,
uric acid levels in serum had a tendency to significantly
decrease under CSE and metformin in LT2D. In diabetic
animals, a better correlation coefficient between urine
a1-microglobulin and serum uric acid (Pearson coef-
ficient¼ .811) compared to that between urine albumin
and serum uric acid (Pearson coefficient¼ .399) may
support the concept that high serum uric acid can
cause damage to the kidneys and lead to proteinuria; it
may also suggest that a1-microglobulin was a better
and a more sensitive candidate for the evaluation of
kidney alleviation in the early stages of diabetes
although the stability of a1-microglobulin in acidified
urine may also be a factor.24,27
Without affecting blood and urine markers in ET2D,
metformin was able to lower urinary glucose and urea,
as well as serum urea and BUN levels, in LT2D. Aspirin
significantly lowered urea and BUN in sera of LT2D rats
but there was an unfavorable significant increase of cre-
atinine in blood, indicating poor clearance of creatinine
Figure 5. H & E stained kidney histopathology micrographs of NIA/STZ (ET2D) group of rats before and after treatment with CSE
and metformin (400). E-T2D caused extensive irregularity in the glomerular basement membrane (GBM) and mild scleronecrosis.
Treatment with CSE and metformin seemed to improve the condition.
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by the kidneys; there was a decrease in urine volume,
glucose, uric acid, urea, and total protein levels of Asp-
STZ group compared to the STZ group.
With regard to histology, renal tissues from ET2D and
LT2D were different from normal and from each other.
High intracellular glucose (glucotoxicity), deranged glu-
cose metabolism, inflammation, oxidative stress, fibrosis
and increased glomerular capillary pressure5,28 can
cause damage to renal structural components, the
extent of which correlates with urinary albumin
Figure 6. H & E stained kidney histopathology micrographs of STZ group of rats before and after treatment with CSE, metformin
and aspirin (400). LT2D led to a widening of urinary space, overlaying cellular crescent fibrinohyalinosis, dilatation, vasculariza-
tion, and necrosis and leukocyte infiltration. Treatment of STZ group with chicory may have improving effects. Aspirin apparently
did not improve the structural situation; more dilatation and vascularization was observed, urinary space was still large and hyali-
nization was present.
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excretion.29 Some researchers have found the histo-
logical damages to kidneys to be unimpressive in STZ-
induced diabetes attributing them to STZ toxicity, but
Danda et al. found that low-dose STZ caused greater
kidney lesions than high-dose STZ and concluded that
the structural damage was not due to STZ nephrotox-
icity.7,30 Similarly, our results showed that urine albumin
and total protein increased more significantly in ET2D
than in LT2D. Among the common histological findings
in diabetic kidney,5 we observed a widening of urinary
space, overlaying cellular crescent fibrinohyalinosis, dila-
tation, vascularization, necrosis, and leukocyte infiltra-
tion. CSE seemed to alleviate the morphology in both
types of T2D. This effect of CSE may originate from its
anti-inflammatory effects 16,31 or its ability to reduce
serum levels of uric acid or the size of glomerulus diam-
eter that occurred in LT2D. Elevated uricemia has been
linked to wall thickening, protein deposition, and
smooth muscle cell proliferation in the kidney.7
Despite the favorable effects on urine levels of glu-
cose, uric acid, urea, and total proteins, aspirin seemed
to increase the glomerular diameter. Glomerular
enlargement is an important risk factor for various types
of kidney diseases including chronic kidney disease
(CKD).32 Metformin appeared to decrease the structural
lesions as it has been reported to ameliorate patho-
logical renal injury in T2D and prevent kidney
cancer.33–35
Increased glycosuria in diabetes can be associated
with increased levels of sodium-dependent glucose
transporters, including SGLT1 and SGLT2 proteins.36
Western blot analysis of these proteins suggested
greater protein levels of both SGLT1 and SGLT2 in STZ-
and NIA/STZ-induced diabetes in rats (Figure 7) in
agreement with other studies.37 Despite the reported
diuretic properties, chicory did not decrease the expres-
sion levels of SGLT1 nor SGLT2 proteins.38 As inhibition
of both SGLT2 and SGLT1 inhibitors should lead to
increased excretion of glucose in urine, the inability of
CSE, metformin, and aspirin to inhibit SGLT2 and
SGLT1protein expression could have been inferred from
the observation that the amount of glucose in 24 h
urine samples showed a continuous decrease (not an
increase) during treatment.39 Instead, CSE tended to
increase the expression of SGLT1. The effect of metfor-
min and aspirin on SGLT1 or SGLT2 proteins were not
evaluated, but metformin has been shown to increase
the SGLT1 levels in duodenum and jejunum.40 Diuretic
property of chicory may be related to its ability to
slightly increase GRF (NIA/STZ vs. CSE-NIA/STZ, p¼ .057).
In summary, chicory benefited both types of diabetes
with regard to histology, reduced serum uric acid and
glomerular diameter in LT2D and lowered urinary a1-
microglobulin in ET2D. The absolute values of albumin,
a1-microglobulin or total protein in urine, not their cre-
atinine ratios, were better markers for early renal dam-
age. CSE was able to reverse kidney damage judging
from its ability to significantly lower urine a1-microglo-
bulin and improve histological appearance.
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